LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients

NCT04728932 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

206

Enrollment

OTHER

Sponsor class

Conditions

Cardiogenic Shock
Extracorporeal Membrane Oxygenation Complication

Interventions

DRUG: Levosimendan
DRUG: Placebo of Levosimendan

Sponsor

Assistance Publique - Hôpitaux de Paris